Aptose Biosciences’ (APS) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of Aptose Biosciences Inc (TSE:APS) in a research note published on Friday, StockTargetPrices.com reports. Royal Bank Of Canada currently has a C$24.00 price target on the stock.

Aptose Biosciences (TSE:APS) remained flat at $2.92 during midday trading on Friday. The stock had a trading volume of 18,401 shares. The company’s 50-day moving average price is $2.91 and its 200-day moving average price is $3.21. Aptose Biosciences has a 12-month low of $2.51 and a 12-month high of $8.33. The firm’s market capitalization is $37.64 million.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Stock Target Prices

Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.